Vanda Pharmaceuticals Inc. VNDA

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
62/100
Moderate

Ranked against 712 peers in Biotechnology

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing … Full VNDA analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.93), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.77), indicating reliable business model.

Key risks

  • Liquidity Concerns Liquidity is concerning (score 0.27), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
56
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where VNDA ranks in Biotechnology

Vanda Pharmaceuticals Inc. ranks #80 of 713 scored companies in Biotechnology by moat score — the top 11%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
76 Protalix BioTherapeutics, Inc. PLX 63/100 Moderate
77 Champions Oncology, Inc. CSBR 63/100 Moderate
78 Sutro Biopharma, Inc. STRO 62/100 Moderate
79 Heron Therapeutics, Inc. HRTX 62/100 Moderate
80 Vanda Pharmaceuticals Inc. VNDA 62/100 Moderate
81 Denali Therapeutics Inc. DNLI 62/100 Moderate
82 Monte Rosa Therapeutics, Inc. GLUE 62/100 Moderate
83 ADC Therapeutics SA ADCT 62/100 Moderate
84 Legend Biotech Corporation LEGN 62/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How VNDA scores on the Corporate Default defenses

Pricing Power

Score 56 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 69 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 83 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 44 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 69 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 56 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding VNDA's moat

What is Vanda Pharmaceuticals Inc.'s moat score?

Vanda Pharmaceuticals Inc. (VNDA) scores 62 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #80 of 713 scored companies in Biotechnology, the top 11%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (83/100) and its weakest is Capital Efficiency (44/100).

How does Vanda Pharmaceuticals Inc. compare with other Biotechnology companies?

Vanda Pharmaceuticals Inc. ranks #80 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Heron Therapeutics, Inc. (HRTX) at 62 just above it and Denali Therapeutics Inc. (DNLI) at 62 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Vanda Pharmaceuticals Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Vanda Pharmaceuticals Inc.?

The Corporate Default template measures 6 defenses, and VNDA scores: Pricing Power (56), Cost Advantage (69), Customer Stickiness (83), Capital Efficiency (44), Resilience (69), Scale & Market Position (56). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000